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Effect of Her2 Expression on Nupl2 Protein
in Cervical Cancer Cells
Mary E. Eichholz, Margaret J. Ballou, Tristan J. Haight,
Jennifer L. Minton, Ryan N. Oates, & Jacob J. Adler
Brescia University
Abstract: Recurring cervical cancer patients frequently present overexpressed Human Epidermal
Growth Factor Receptor 2 (HER2) protein, which promotes the growth of the cancer. Some HER2expressing cells and cervical cancer patients have enhanced gene expression of Nucleoporin-like 2
(NUPL2). As part of the nuclear pore complex, the NUPL2 protein serves to selectively export
substances from the nucleus to the cytoplasm. In this experiment, HER2 was expressed in cervical
cancer cells to examine its effect on NUPL2 protein expression and localization. Interestingly, there
was no difference in NUPL2 protein levels between HER2-expressing and non-expressing cells.
Importantly, consistent instances of NUPL2 protein localization specific to the nucleus occurred in
a large sampling of HER2-expressing cells. This is significant because it suggests a mechanism as
to how HER2 promotes excessive cell growth, via changes in NUPL2 localization, potentially
impacting its function and ability to selectively export substances that modulate cell growth.

Keywords: HeLa Cells, nucleoporins, nucleus, immunoblot, immunofluorescence
Cervical cancer is the fourth leading cause of cancer deaths
in women worldwide (Bray et al., 2018). Frequently, patients
with recurring cervical cancer have highly expressed Human
Epidermal Growth Factor Receptor 2 (HER2) protein (ChavezBlanco et al., 2004), a documented powerful cancer driver
(Moasser, 2007). Many types of cancers are promoted by
deregulating cellular nucleoporins, which are proteins of the
nuclear pore complex involved in the transportation of gene
transcripts, regulation of transcription, and chromatin access
(Köhler & Hurt, 2010; Kau et al., 2004). Importantly, one of
these nucleoporins, Nucleoporin-like 2 (NUPL2), shows
enhanced gene expression in HER2-positive breast cancer cell
lines and tissues (Kalari et al., 2013; Wilson et al., 2002). No
published data sets exist comparing HER2-positive cervical
cancers and NUPL2 gene expression; however, cervical cancer
patient samples do present significantly higher NUPL2 gene
expression compared to control samples via microarray analysis
(Long et al., 2017). Additionally, the RNA transport pathway (of
which NUPL2 protein is a member) was found to be a key
mechanism involved in the initiation, progression, and
metastasis of cervical cancer (Long et al., 2017).
Interestingly, the NUPL2 gene is amplified in 1% of cervical
cancer patients and shows higher gene expression levels
compared to controls according to cBioPortal for Cancer
Genomics (Cerami et al., 2012; Gao et al., 2013). However,
cervical squamous cell carcinoma patients show no significant
difference in NUPL2 gene expression between cancer grades,
stages, nor survival according to UALCAN web-portal
(Chandrasekhar et al., 2017). Together, these large data set

studies have suggested a possible link between HER2 expression
and NUPL2 protein in cervical cancer, but this connection has
not been reported. Based upon the data independently
demonstrating cervical cancer and HER2-expression changes to
gene expression of NUPL2, and the importance of NUPL2
localization for its function, here we examined the protein levels
of NUPL2 with immunoblot and its localization via
immunofluorescence in response to HER2 overexpression in
HeLa cells. In the current study, we sought to examine whether
the expression of HER2 could modify the protein expression, or
the location of NUPL2 protein, or both, and as a result, could
impact the transport, regulation, and access of genes involved in
cancer growth.
Method
Cell Culture
HeLa cells were grown in DMEM with Glutamax (Gibco
10565018) supplemented with Fetal Bovine Serum (10%) (FBS)
(Atlanta Biologicals) and Antibiotic-Antimycotic (Gibco
15240062). For immunoblot experiments, cells were plated at
70,000 cells/well on a 6 cm plate. For immunofluorescence
experiments, cells were plated at 10,000 cells/well on an 8-well
chamber slide. For both experiments, cells were grown for 24
hours. Plasmid DNA, either control pcDNA3.1-EGFP or
pERBB2-EGFP (Addgene plasmid # 39321), was transfected
with Lipofectamine 3000 (ThermoFisher Scientific L3000001)
via manufacture instructions. Cells were allowed to grow for 24
hours then used for assays.
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(ThermoFisher R37177) was diluted 1:500 in 3% Goat Serum
and incubated for 30 minutes at 4 °C in dark. DAPI Stain
(Chemical FL 341 Blue) (Pierce 62248) was diluted to a final
concentration 1 μg/mL and applied to each well for 8 minutes at
room temperature in dark. Between each step above, wells were
washed 3 times with PBS. Chamber slides were dismantled and
washed twice gently with ultrapure water. Slides were dried and
mounted with coverslips with ProLong Glass Antifade Mountant
(Invitrogen P36982) per manufacturer directions. Slides were
imaged using the EVOS FL imaging system (Life Technologies).
EVOS LED GFP light cube (AMEP4651) was used to analyze
GFP-expressing HeLa cells. EVOS LED TexasRed light cube
(AMEP4655) was used to analyze NUPL2/Alexa Fluor 594.
EVOS LED DAPI light cube (AMEP4650) was used to analyze
DAPI Stain. Analysis of immunofluorescence data was
completed using ImageJ (https://imagej.nih.gov/ij/download/).

Immunoblot
HeLa cells on 6 cm plates were washed twice with
phosphate buffered saline (PBS) on ice and scraped into a
microcentrifuge tube. Cells were microcentrifuged at 4 °C at 600
X g for 2 minutes and then the supernatant was discarded. The
cell pellets were resuspended with a RIPA lysis buffer (50 mM
Tris-HCl pH 7.4, 1% NP-40, 0.5% Sodium-deoxycholate, 0.1%
SDS, 150 mM NaCl, 2 mM EDTA pH 8.0, 50 mM NaF)
supplemented with a protease inhibitor cocktail (Sigma S88202TAB) then passed 50 times with a P200 micropipette. Samples
were placed on dry ice for 2 minutes, then removed from dry ice
and warmed quickly. Samples were passed 50 times again with
a P200 micropipette and placed back on dry ice for 2 minutes.
Samples were warmed quickly and then placed on ice for 10
minutes. Samples were microcentrifuged at 4 °C for 10 minutes
at 20,000 X g. The supernatant was removed and used with
common SDS-PAGE and liquid transfer of proteins on
nitrocellulose protocols. Anti-GFP antibody (Sigma G6539) was
used at a 1:1000 dilution in PBS-Tween. Anti-NUPL2 antibody
(Abcam EPR16545) was used at a 1:1000 dilution in PBSTween. Anti-GAPDH antibody (Cell Signaling 5174T) was used
at a 1:1000 dilution in PBS-Tween. All antibodies were
incubated with nitrocellulose blots overnight on a rocking
platform at 4 °C. Anti-Rabbit and anti-Mouse IgG HRP-linked
antibodies (Cell Signaling 7074 and 7076) were used at 1:1000
dilutions and incubated at room temperature for 30 minutes on a
rocking platform. HRP Conjugate Substrate Kit (BioRad
1706431) was used to detect HRP secondary antibodies via
manufacturer directions. Images were acquired using the gel
imaging system (BioRad Gel Doc 2000 Chemi Doc 1708126).

Results
Since several studies indicate changes to NUPL2 gene
expression in HER2-positive breast samples (Kalari et al., 2013;
Wilson et al., 2002), and in cervical cancer patients (Long et al.,
2017), the protein levels of NUPL2 were examined via
immunoblot. NUPL2 protein levels remained unchanged
between HER2-expressing and non-expressing HeLa cells
(Figure 1). This indicates an inability for high levels of HER2 to
compromise the normal protein expression or stability of NUPL2
in these cells.
Previous work showed that NUPL2 protein localized
primarily around the nucleoplasm, and some cytoplasmic
staining in HeLa cells according to The Human Protein Atlas
(Thul et al., 2017). NUPL2 presents its functionality in the
nucleus as a part of the nuclear pore complex (Köhler & Hurt,
2010); thus immunofluorescence was used to examine the
localization of NUPL2 in HER2-expressing cells (Figure 2).
Importantly, NUPL2 localized within the nucleus in 65% of cells
expressing HER2 (N = 100), compared to just 20% access in the
non-expressing cells (N = 180) (Table 1). Interestingly, only in
HER2-expressing cells did NUPL2 exclusively localize to the
nucleus. There was a decreased corresponding 56% change in
cytosolic localization of NUPL2 in the HER2-expressing cells
compared to non-expressing cells. Together these data indicate a
change in localization of NUPL2 more towards the nucleus in
HER2-expressing cells.

Immunofluorescence
HeLa cells on chamber slides were fixed with a 4%
paraformaldehyde solution in PBS for 10 minutes at room
temperature. Cells were then permeabilized with a 0.5% Tween20 in PBS solution for 10 minutes at room temperature. Finally,
cells were blocked in a 3% Goat Serum (Sigma G9023) in PBS
overnight at 4 °C. Prior to each step above, cells were washed 3
times for 3 minutes each with PBS. Fixed cells were then
incubated with the primary antibody NUPL2 (Abcam
EPR16545) diluted 1:100 in 3% Goat Serum for 1 hour at 4 °C.
Secondary antibody Goat anti-Rabbit Alexa Fluor 594
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Figure 1. Immunoblot detection of NUPL2 protein in HER2-expressing HeLa cells. HeLa cells transfected with GFP-tagged vector
control or with GFP-tagged HER2 were then harvested for protein and used for immunoblot using antibodies specific for NUPL2, GFP,
and GAPDH. Three independent samples are provided per condition.

Figure 2. Immunofluorescence detection of NUPL2 protein in HER2-expressing HeLa cells. HeLa cells transfected without or with
GFP-tagged HER2 (green) using an antibody for NUPL2 (red). Cells were co-stained for nuclei (blue) in overlay with the other two
channels (merge).
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Nucleus Only

Both

Cytosol Only

Control
(N = 180)

0%

20 %

80 %

HER2
(N = 100)

14 %

51 %

35 %

Table 1. NUPL2 localization in HER2-expressing HeLa cells. The quantification of localization of NUPL2 (red) in HeLa cells
transfected without (Control) (N = 180 cells) or with HER2 (N = 100 cells). Cells were analyzed by three separate investigators in the
blind. Nucleus Only = residing visibly only in nucleus; Cytosol only = residing visibly only outside the nucleus; Both = residing visibly
in and out of the nucleus. Representative images of NUPL2 localization for each group are provided.

The immunofluorescence data paints an intriguing role of
HER2 expression in the localization of NUPL2 protein. Studies
have shown that when NUPL2 protein and other nucleoporins
are deregulated, these proteins function to promote cell growth
and cancer proliferation (Nofrini et al., 2016). The localization
change of NUPL2 to the nucleus suggests that HER2 expression
could impact the functionality of NUPL2 in HeLa cells.
Interactome enrichment studies have shown that other
nucleoporins could be deregulated in HER2-positive tumors
(Kalari et al., 2013; Long et al., 2017). In conclusion, these
findings provide initial information about the relationship
between NUPL2 protein and HER2 expression in cells. This data
provides the foundational knowledge to explore NUPL2 and
other nucleoporins and isolate their relationships in HER2positive recurring cervical cancer patients. Perhaps NUPL2
could indicate a viable mechanistic target for understanding and
unlocking new nucleoporin-related gene therapy options.

Discussion
Prior to this investigation, there were no published studies
examining the impact of HER2 expression on NUPL2 protein in
any cell line. In fact, in cervical cancer cells, NUPL2 protein
levels and localization have only been reported previously in
HeLa cells found on (Abcam EPR16545) and The Human
Protein Atlas (Thul et al., 2017), and not in cervical cancer cell
lines expressing high HER2 (SiHa, C33A, CaSki) (NarisawaSaito et al., 2006). Future studies on HER2 in cervical cancer
might examine these cell lines with higher HER2 expression for
NUPL2 protein to see if there are relative change in basal levels.
This study is the first to characterize the role of HER2 expression
on NUPL2 protein with immunoblot and immunofluorescence
data. The data clearly demonstrates that expression of HER2
does not influence the protein levels of NUPL2 in HeLa cells.
This is critical information for the field, as previous studies
demonstrated a change in the NUPL2 gene expression levels in
HER2-positive breast tissues via cDNA microarray and RNASeq data sets (Wilson et al., 2002; Kalari et al., 2013) and in
cervical cancer patient samples (Long et al., 2017). It is likely
that other unknown tissue- and organ-specific factors such as
hormones or post-translational processing may be important to
the regulation of NUPL2 protein production, of which HER2
may be a corresponding factor.
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